Bisphosphonate Drug Holiday and Fracture Risk: Reviewing the Evidence
Tóm tắt
This paper reviews evidence in support of or counter to the use of bisphosphonate (BP) drug holiday to minimize the occurrence of rare adverse events such as atypical femoral fracture, while maintaining the osteoporosis-related fracture prevention benefit conferred by the medication. Fracture prevention benefit achieved with 3–5 years of BP treatment appears to be maintained during holiday for women at low to moderate risk of fracture. Women with bone mineral density T-score < − 2.5 or prior fragility fracture remain at high risk for fracture and continuation of therapy is advised. Additionally, evidence suggests that duration of BP use, level of adherence to therapy, and length of holiday may also influence fracture risk during holiday. There are few studies on AFF risk during drug holiday, but the limited evidence suggests a rapid decline in risk within the first 1–2 years of holiday. BP drug holiday appears to be a reasonable part of osteoporosis treatment strategy for women at relatively low risk of osteoporosis-related fracture as assessed after initial treatment, while higher risk women may benefit from continued therapy rather than a BP holiday. Greater understanding of the influences of BP treatment duration and holiday length, and their interaction, can inform more individualized treatment decision-making.
Tài liệu tham khảo
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826–31. https://doi.org/10.1001/archinte.168.8.826.
Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res. 2015;30(12):2179–87. https://doi.org/10.1002/jbmr.2565.
Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, et al. Hip fracture trends in the United States, 2002 to 2015. Osteoporos Int. 2018;29(3):717–22. https://doi.org/10.1007/s00198-017-4345-0.
Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis. 2010;1(3):115–28. https://doi.org/10.1177/2040622310374783.
Cummings SR, Santora AC, Black DM, Russell RGG. History of alendronate. Bone. 2020;137:115411. https://doi.org/10.1016/j.bone.2020.115411.
Giusti A, Papapoulos SE. Bisphosphonates for postmenopausal osteoporosis. In: Bilezikian JP, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 9th ed. Hoboken: John Wiley & Sons, Inc; 2019.
Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97(7):2272–82. https://doi.org/10.1210/jc.2012-1027.
Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355(19):2048–50. https://doi.org/10.1056/NEJMc062268.
Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349–53. https://doi.org/10.1302/0301-620X.89B3.18146.
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729–37. https://doi.org/10.1002/jbmr.1893.
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94. https://doi.org/10.1002/jbmr.253.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. https://doi.org/10.1002/jbmr.1998.
Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102. https://doi.org/10.1359/jbmr.081247.
Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010;95(12):5258–65. https://doi.org/10.1210/jc.2010-1571.
Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71. https://doi.org/10.1056/NEJMoa1001086.
Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012;27(5):977–86. https://doi.org/10.1002/jbmr.1550.
Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther. 2011;33(11):1659–67. https://doi.org/10.1016/j.clinthera.2011.09.006.
Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011;26(5):993–1001. https://doi.org/10.1002/jbmr.288.
Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353–62. https://doi.org/10.1007/s00198-008-0805-x.
Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172(12):930–6. https://doi.org/10.1001/archinternmed.2012.1796.
Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783–9. https://doi.org/10.1001/jama.2011.190.
Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–37. https://doi.org/10.1056/NEJMoa1010650.
Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011;22(3):993–1001. https://doi.org/10.1007/s00198-010-1512-y.
Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ. 2016;353:i3365. https://doi.org/10.1136/bmj.i3365.
• Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743–53. https://doi.org/10.1056/NEJMoa1916525. An important study of a population-based cohort with a large number of AFF that includes analysis of the effect of BP discontinuation and AFF reduction.
Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100–7. https://doi.org/10.3109/17453674.2015.1004149.
Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–50. https://doi.org/10.1002/jbmr.1719.
•• Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333–68. https://doi.org/10.1210/er.2018-00001. A thorough and comprehensive presentation of the entire body of science related to AFF to date.
DiGiulio M, Loveless T, Heider G, Fagan K, Porsche B. Bisphosphonate drug holidays: one size does not fit all. Nurse Pract. 2020;45(3):50–5. https://doi.org/10.1097/01.NPR.0000605524.34681.e7.
•• Hayes KN, Winter EM, Cadarette SM, Burden AM. Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med. 2021;10(5). https://doi.org/10.3390/jcm10051140. A nice review paper that includes consideration of factors such as BMD, fall risk, and other patient characteristics for inclusion in decision-making about drug holiday.
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38. https://doi.org/10.1001/jama.296.24.2927.
Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19(3):365–72. https://doi.org/10.1007/s00198-007-0460-7.
Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99(12):4546–54. https://doi.org/10.1210/jc.2014-1971.
Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19(11):1613–20. https://doi.org/10.1007/s00198-008-0604-4.
Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, et al. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res. 2018;33(7):1252–9. https://doi.org/10.1002/jbmr.3420.
• Pfeilschifter J, Steinebach I, Trampisch HJ, Rudolf H. Bisphosphonate drug holidays: risk of fractures and mortality in a prospective cohort study. Bone. 2020;138:115431. https://doi.org/10.1016/j.bone.2020.115431. This study of a small cohort evaluates the association of duration of drug holiday with fracture and mortality risk, and identifies prior vertebral fracture as an additional factor in decision-making about holiday.
• Solling AS, Christensen DH, Darvalics B, Harslof T, Thomsen RW, Langdahl B. Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. Osteoporos Int. 2021;32:1103–15. https://doi.org/10.1007/s00198-020-05745-x. This large cohort study looked at fracture risk among women with at least 5 years of BP treatment, comparing continuers with discontinuers, and observed no difference in risk of fracture between the two groups.
Nayak S, Greenspan SL. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int. 2019;30(4):705–20. https://doi.org/10.1007/s00198-018-4791-3.
Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med. 2019;171(1):37–50. https://doi.org/10.7326/M19-0533.
Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976–82. https://doi.org/10.1002/jbmr.11.
Mignot MA, Taisne N, Legroux I, Cortet B, Paccou J. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int. 2017;28(12):3431–8. https://doi.org/10.1007/s00198-017-4215-9.
• Curtis JR, Saag KG, Arora T, Wright NC, Yun H, Daigle S, et al. Duration of bisphosphonate drug holidays and associated fracture risk. Med Care. 2020;58(5):419–26. https://doi.org/10.1097/MLR.0000000000001294. A large cohort study of how fracture risk is associated with duration of drug holiday finds that holidays of greater than 2-year duration are associated with increased risk of fractures.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. https://doi.org/10.1080/00273171.2011.568786.
Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–64. https://doi.org/10.1093/aje/kwv254.
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.
Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23–30. https://doi.org/10.1016/j.maturitas.2017.04.008.
Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30(9):1733–43. https://doi.org/10.1007/s00198-019-05002-w.
Strom O, Landfeldt E, Garellick G. Residual effect after oral bisphosphonate treatment and healthy adherer effects–the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2015;26(1):315–25. https://doi.org/10.1007/s00198-014-2900-5.